Cargando…

Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World

The U.S. must assess its pricing and reimbursement system for prescription drugs. The current system is attracting intense scrutiny for various reasons. Drug pricing and reimbursement mechanisms used in other countries are described to assess what an optimal system should entail.

Detalles Bibliográficos
Autores principales:	Goldstein, Daniel A., Sarfaty, Michal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2016
Materias:	Value in Cancer Care
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978557/ https://www.ncbi.nlm.nih.gov/pubmed/27384235 http://dx.doi.org/10.1634/theoncologist.2016-0106

Ejemplares similares

Those Who Pay Have a Say: A View on Oncology Drug Pricing and Reimbursement
por: Newcomer, Lee N.
Publicado: (2016)

Getting Past No in Cancer Care
por: Kolodziej, Michael
Publicado: (2016)

Value-Based Care in Lung Cancer
por: Eaton, Keith D., et al.
Publicado: (2016)

Value: The Next Frontier in Cancer Care
por: Goulart, Bernardo H.L.
Publicado: (2016)

New Frameworks to Assess Value of Cancer Care: Strengths and Limitations
por: Schnipper, Lowell E., et al.
Publicado: (2016)

Financial Toxicity and Societal Costs of Cancer Care: Distinct Problems Require Distinct Solutions
por: Peppercorn, Jeffrey
Publicado: (2017)

End‐of‐Life Care Matters: Palliative Cancer Care Results in Better Care and Lower Costs
por: Dalal, Shalini, et al.
Publicado: (2017)

Addressing Patients’ Priorities as a Strategy to Improve Value
por: Wong, Yu-Ning, et al.
Publicado: (2016)

A Touchy Subject: Can Physicians Improve Value by Discussing Costs and Clinical Benefits With Patients?
por: Wollins, Dana S., et al.
Publicado: (2016)

Managing high-priced biologic agents: challenges and potential solutions
por: Li, Meng, et al.
Publicado: (2021)

376 The Role of Antiretroviral Treatment Patenting on Consumer Pricing: Declining Viral Suppression and Treatment Non-Adherence Among HIV Patients in Los Angeles County
por: Crovetto, Arianna
Publicado: (2022)

Medicare elective surgery outcomes and State prospective reimbursement programs
por: Gaumer, Gary L., et al.
Publicado: (1987)

Pricing and reimbursement of novel oncology drugs in Sweden
por: Haglund, Mattias, et al.
Publicado: (2014)

404 Gaps in Physical Therapists’ and Physical Therapist Assistants Knowledge and Use of the CDC’s STEADI for Falls Risk Screening of Older Adults in the United States
por: Vincenzo, Jennifer L., et al.
Publicado: (2022)

365 Communication about Genetic Testing to Adult Women with a Higher Risk of Cancer in the United States: A Cross-sectional Analysis of the Health Information National Trends Survey (2017-2020)
por: Pottinger, Camille
Publicado: (2022)

Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France
por: Squara, Pierre-Alexandre, et al.
Publicado: (2022)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer
por: Goldstein, Daniel A., et al.
Publicado: (2020)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

241 Utilizing real-world evidence to increase efficiency of randomized controlled trials with application to repurposed therapeutics for COVID-19
por: Haine, Lillian M F, et al.
Publicado: (2022)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023)

272 A Longitudinal, Multi-Method, Pilot Triangulation of Family Intensive Care Unit Syndrome
por: Pignatiello, Grant, et al.
Publicado: (2022)

250 Defining Developmentally High-Risk Full Term and Late Preterm Infants in the Neonatal Intensive Care Unit
por: Carlton, Katherine, et al.
Publicado: (2022)

352 Computational methods for predicting drug combinations for targeting KRAS mutations relevant to non-small cell lung cancer
por: Bruggemann, Liana, et al.
Publicado: (2022)

400 Potential Drug Therapy for Fragile X Tremor/Ataxia Syndrome
por: Brown, Collis, et al.
Publicado: (2022)

Physician pricing and health insurance reimbursement
por: Yett, Donald E., et al.
Publicado: (1983)

Reimbursement and economic factors influencing dialysis modality choice around the world
por: Just, Paul M., et al.
Publicado: (2008)

348 Resting state fMRI connectivity in individuals with aphasia and the role of the inferior frontal gyrus
por: Diedrichs, Victoria, et al.
Publicado: (2022)

442 Repurposing FDA-approved PI3K/Akt Inhibitors to Improve Anti-Cancer Drug Brain Uptake in Glioblastoma Resection Models
por: Rodgers, Louis, et al.
Publicado: (2022)

397 Factors needing attention to implement effective drug treatment in community correctional in Puerto Rico
por: Vega Debien, Graciela D., et al.
Publicado: (2022)

351 Loop-mediated isothermal amplification for the detection of cytomegalovirus infection and drug resistance at the point of care
por: Medina-Rivera, Melisa, et al.
Publicado: (2022)

Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2021)

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
por: Docteur, Elizabeth, et al.
Publicado: (2015)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
por: Gray, Andrew L
Publicado: (2015)

Challenges and opportunities for pharmaceutical pricing and reimbursement policies
por: Vogler, Sabine, et al.
Publicado: (2015)

310 Transcriptomics for gallbladder cancer prognosis
por: Jackson, Linsey, et al.
Publicado: (2022)

Getting Unstuck: Challenges and Opportunities in Caring for Patients Experiencing Prolonged Hospitalization While Stable for Discharge
por: Meo, Nicholas, et al.
Publicado: (2020)

Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States
por: Vogler, Sabine, et al.
Publicado: (2011)

The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q4r6a0fd0e1n90ec420301ppd3